Previous 10 | Next 10 |
– Continued positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history trajectories – – Highly significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarker...
– Company to host conference symposium to discuss its approach to protecting dystrophic muscle featuring key opinion leaders and 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with BMD – Edgewise Therapeutics, Inc., (Nasdaq: EW...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the closing of its upsized underwritten public offering of 13,372,093 shares of its common stock at a price to the public of $10.32 per share, which includes the exercise in full by the underwriters of their option to purchase a...
Edgewise Therapeutics ( NASDAQ: EWTX ) has priced its upsized underwritten public offering of 11,627,907 shares of its common stock at a price of $10.32/share for an expected gross proceeds to be $120M. All of the shares are to be sold by Edgewise Therapeutics. Underwr...
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to the public of $10.32 per share. All of the shares are to be sold by Edgewise Therapeutics. In addition, Edgewise Ther...
Edgewise Therapeutics ( NASDAQ: EWTX ) announced Tuesday its plans to raise $100M in the underwritten public stock offering; price, size and other terms not yet determined. The Colorado-based biopharmaceutical company told underwriters will be granted an overallotment...
Edgewise Therapeutics, Inc., (NASDAQ: EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common stock. In addition, Edgewise Therapeutics intends to grant the underwriters a 30-day option to purcha...
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers s...
- Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle ...
News, Short Squeeze, Breakout and More Instantly...
Edgewise Therapeutics Inc. Company Name:
EWTX Stock Symbol:
NASDAQ Market:
Edgewise Therapeutics Inc. Website:
2024-07-01 09:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-30 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...